Update on diagnosis and management of essential thrombocythemia

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 4, 2006, Pages 430-436

  Gisslinger, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anagrelide; Cytoreductive therapy; Essential thrombocythemia; Hydroxyurea; Interferon ; JAK2 V617F mutation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BLOOD CLOTTING FACTOR 5 LEIDEN; CD11B ANTIGEN; FIBRINOGEN; GLYCOPROTEIN IB; HYDROXYUREA; JANUS KINASE 2; LACTATE DEHYDROGENASE; PEGINTERFERON; POTASSIUM; PROTEIN C; PROTEIN S; PROTHROMBIN; VON WILLEBRAND FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ARTERY OCCLUSION; ARTICLE; BLEEDING; DIZZINESS; DRUG CHOICE; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROMELALGIA; FETUS WASTAGE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIFE EXPECTANCY; MENTAL DISEASE; MORBIDITY; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; PARESTHESIA; POTASSIUM BLOOD LEVEL; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; SECOND CANCER; SMOKING; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOSIS; VON WILLEBRAND DISEASE;

AGE FACTORS; ANTINEOPLASTIC AGENTS; ASPIRIN; DRUG ANTAGONISM; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LIFE EXPECTANCY; MALE; QUINAZOLINES; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 33745700672     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942764     Document Type: Article

References (38)

1. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma 2006;47:381-396
2. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia very or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003;139:470-475
3. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761
4. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ III. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 1994;47:89-93
5. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61:10-15
6. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663
7. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in well defined geographical area. Eur J Haematol 2000;65:132-139
8. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 1999;245:295-300
9. V617F: When to order the test and how to interpret the results. Leuk Res 2006; In press
10. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-152
11. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-562
12. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-154
13. Jensen MK, de Nully Brown P, Lund BV, Nielsoen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000;110:116-124
14. Cardin F, Graffeo M, McCormick PA, McIntyre N, Burroughs A. Adult "idiopathic" extrahepatic venous thrombosis. Importance of putative "latent" myeloproliferative disorders and comparison with cases with known etiology. Dig Dis Sci 1992;37:335-339
15. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587-591
16. Gisslinger H, Muellner M, Pabinger I, et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica 2005;90:408-410
17. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997;56:168-172
18. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993;43:1107-1110
19. Michiels JJ. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Pathol Biol (Paris) 2003;51:167-175
20. Kessler CM, Klein HG, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982;50:157-167
21. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549-556
22. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol 2001;80:74-78
23. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk thrombosis. N Engl J Med 1995;332:1132-1136
24. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Interferon in essential thrombocythaemia. Br J Haematol 1991;79(suppl):42-47
25. Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-2246
26. van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 1997;99:832-836
27. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2004;128:275-290
28. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol 2002;40:1761-1768
29. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266
30. Neunteufl T, Heher S, Stefenelli T, Pabinger I, Gisslinger H. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001;115:354-359
31. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66:143-151
32. Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6
33. Gisslinger H, Rodeghiereo F, Ruggeri M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999;105:551-555
34. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-424
35. Griesshammer M, Klippel S, Strunck E, et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 2004;83:364-370
36. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
37. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232
38. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45